To evaluate the therapeutic effect of China-made recombinant human growth hormone （r-hGH） in children with growth hormone deficiency （GHD） and to investigate the utilities of various biochemical parameters in GHD diagnosis and treatment. Methods Our study comprises of 30 normal children and 71 GHD children treated with China-made r-hGH substitution therapy 0.1 IU·kg-1·d-1 for 6 months. Serum insulin-like growth factor-1 （IGF-1）

insulin-like growth factor binding protein 3 （IGFBP-3）

bone turnover markers （Ost

ICTP）

and anti-growth hormone antibody （GHAb） were detected before and after r-hGH treatment. Results After the first 3 and 6 months of treatment

growth velocities of GHD children were significantly increased （13.1 ± 3.7 and 12.6 ± 3.6 cm/year） compared with pretreatment values （2.9 ± 0.8 cm/year

P < 0.01）. GHD Children had obviously reduced serum levels of IGF-1

IGFBP-3

and bone turnover markers （Ost

ICTP） compared with normal controls （P < 0.01）

and these biochemical parameters improved significantly after treatment （P < 0.01）. Growth hormone antibodies were positive in 17 of 45 cases after treatment by binding capacity detection. The binding percentage of growth hormone an-tibody which was increased more than 30% after the treatment showed a negative correlation with growth velocity （P < 0.01）. Conclusions （1） The growth stimulating effect and safety were confirmed in using China-made r-hGH in the treatment of GHD children for 6 months. （2） The measurements of serum IGF-1 and IGFBP-3 may serve as useful parameters in the diagnosis of GHD. （3） Serum Ost and ICTP are useful laboratory criteria for evaluating the effect of r-hGH therapy in the early stage. （4） It is necessary to monitor serum levels of GHAb during r-hGH therapy.